Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Up 13.4% in June

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) saw a large increase in short interest in June. As of June 30th, there was short interest totalling 9,300 shares, an increase of 13.4% from the June 15th total of 8,200 shares. Based on an average daily volume of 13,800 shares, the short-interest ratio is presently 0.7 days.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

An institutional investor recently bought a new position in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new stake in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 980 shares of the company’s stock, valued at approximately $25,000. Hedge funds and other institutional investors own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Price Performance

NASDAQ:CALT traded down $0.78 during trading hours on Monday, reaching $38.72. The stock had a trading volume of 2,333 shares, compared to its average volume of 10,894. The company has a debt-to-equity ratio of 8.46, a quick ratio of 2.62 and a current ratio of 2.69. Calliditas Therapeutics AB has a 52 week low of $15.25 and a 52 week high of $41.90. The company has a 50 day moving average price of $33.88 and a two-hundred day moving average price of $25.96. The stock has a market capitalization of $1.15 billion, a PE ratio of -20.93 and a beta of 1.77.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last released its quarterly earnings data on Thursday, May 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74). The firm had revenue of $28.43 million during the quarter, compared to the consensus estimate of $35.78 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. As a group, sell-side analysts anticipate that Calliditas Therapeutics AB will post -0.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CALT. HC Wainwright reissued a “neutral” rating and issued a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. Jefferies Financial Group reissued a “hold” rating and issued a $39.00 price target (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. Stifel Nicolaus reissued a “hold” rating and issued a $40.00 price target (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. Citigroup reaffirmed a “neutral” rating and issued a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research note on Friday, May 31st. Finally, Lifesci Capital downgraded Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 28th. Six research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $35.00.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.